in vitro News and Research

RSS

Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate

Biodel Inc. today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an oral presentation today at the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, Nandini Kashyap, director of novel drug delivery at Biodel, described results of in vitro and in vivo studies with diabetic pigs which compared the use of BIOD620 to Lantus® (insulin glargine).

13 Jul 2010

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.

13 Jul 2010

Accuri Cytometers announces completion of $6 million Series E preferred stock financing

Accuri Cytometers, Inc., a world leader in providing life science researchers with easy-to-use, cost-effective flow cytometers, today announced completion of a $6 million Series E preferred stock financing. The financing included current investors Arboretum Ventures, Baird Venture Partners, Fidelity Biosciences, Flagship Ventures and the InvestMichigan! Program co-managed by Credit Suisse.

12 Jul 2010

MiCK assay effective in predicting best chemotherapy response for Endometrial Cancer patients: Study

Oncologists working with DiaTech Oncology have published the results of a comprehensive study to determine the effectiveness of the Microculture Kinetic (MiCK) assay for apoptosis in predicting the best chemotherapy response for Endometrial Cancer patients. (Journal of Gynecologic Oncology March 2010 Mar)

12 Jul 2010

FDA grants Catheter Connections 510(k) clearance for DualCap disinfecting product

Catheter Connections, Inc., a manufacturer of innovative vascular access and infection control products, today announced that the U.S. Food and Drug Administration (FDA) has granted the company 510(k) clearance to market its DualCap™ product. DualCap is the only device that nests two disinfecting caps together - for both IV access points, the needleless injection site (NIS) and the male luer at the end of the IV tubing. Previously overlooked as a route of microbial colonization, Catheter Connections has developed the first disinfecting cap for the male luer.

12 Jul 2010

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

A new system for the controlled delivery of pharmaceutical drugs has been developed by a team of University of Rhode Island chemical engineers using nanoparticles embedded in a liposome that can be triggered by non-invasive electromagnetic fields.

9 Jul 2010

Musashi 2 protein predicts progression of AML and CML, identify researchers

Researchers at Whitehead Institute and Children's Hospital Boston have identified a protein, called Musashi 2, that is predictive of prognosis in acute myeloid leukemia and chronic myeloid leukemia patients.

9 Jul 2010

Roche Molecular Systems receives FDA clearance for new LightCycler MRSA Advanced Test

Roche Molecular Systems, Inc. announced today that the U.S. Food & Drug Administration (FDA) cleared its new LightCycler® MRSA Advanced Test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) for clinical use in the United States.

9 Jul 2010

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

International Stem Cell Corporation and Sankara Nethralaya, announced today commencement of a collaboration to develop ISCO's "CytoCor™" stem cell-derived corneal tissue. The goal is to use CytoCor to treat corneal blindness and vision impairment. "This is one more step in ISCO's stated plan of building its portfolio of therapeutic agents through strategic alliances throughout the world," said Chairman, Ken Aldrich.

7 Jul 2010

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

PolyMedix, Inc., an emerging biotechnology company focused on developing new therapeutic drugs to treat acute cardiovascular disorders and infectious diseases, has received a grant from the National Institute of Health (NIH) to support the development of defensin-mimetic antimicrobial compounds for the treatment of malaria.

7 Jul 2010

Research could lead to remote stimulation of cells to treat cancer or diabetes

Clusters of heated, magnetic nanoparticles targeted to cell membranes can remotely control ion channels, neurons and even animal behavior, according to a paper published by University at Buffalo physicists in Nature Nanotechnology.

7 Jul 2010

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

A multi-disciplinary team of international researchers from Ghent University in Belgium, National Human Genome Research Institute (NHGRI) in the US, Imperial College London in the United Kingdom, and INSERM in France have uncovered a novel molecular pathway that regulates invasive growth and metastasis in estrogen receptor-positive breast cancer.

6 Jul 2010

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Neogenix Oncology announced today that the company has filed a patent application with the U.S. Patent and Trade Office (USPTO) for the 16C3 antigen. The Company believes that this antigen is tumor specific for pancreatic and colorectal tumors; and, based on preliminary clinical data, may also have diagnostic utility as a biomarker for these cancers.

3 Jul 2010

Clemizole can yield high-level synergy with protease inhibitor class: Research

Eiger BioPharmaceuticals, Inc., a biotechnology company developing antiviral therapies, announced today the publication of research from the lab of Stanford scientist and Eiger Founder, Dr. Jeffrey Glenn, M.D., Ph.D. and colleagues entitled, "The Hepatitis C Virus (HCV) NS4B RNA Binding Inhibitor Clemizole is Highly Synergistic with HCV Protease Inhibitors".

2 Jul 2010

IRIS submits 510(k) application for clearance of iChemVELOCITY and iRICELL Urinalysis Workstation

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Diagnostics Division submitted on June 30, 2010, a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for its iChem®Velocity™ Automated Urine Chemistry Analyzer and iRICELL® Urinalysis Workstation.

1 Jul 2010

Babies born after IVM fertility treatment more likely to be born larger than normal

A review of studies of babies born after in vitro maturation (IVM) fertility treatment has suggested that they are more likely to be born larger than normal and to have more difficult births requiring more obstetric interventions such as caesareans.

1 Jul 2010

Individual variants of environmental toxins can affect body's hormone systems: Research

Marianne Kraugerud's doctoral research has led to the discovery that individual variants of the environmental pollutants PCB and PFC can affect several of the body's hormone systems in a more complex way than previously supposed. Humans and animals are constantly exposed to these toxins through the food they eat and the air they breathe. Kraugerud concludes that the impact of these pollutants should be taken into account when carrying out risk appraisals of PCB and PFC.

1 Jul 2010

Celsis IVT files patent infringement lawsuit against Invitrogen, CellzDirect

Celsis In Vitro, Inc. announced today that it has filed a patent infringement lawsuit against Invitrogen Corporation and CellzDirect, Inc. in the United States District Court for the Northern District of Illinois in Chicago and has moved for a preliminary injunction. Invitrogen, the parent of CellzDirect, is itself a wholly-owned subsidiary of Life Technologies of Carlsbad, California.

1 Jul 2010

New guide to get pregnant

Infertility affects about 7 million Americans -- that's about one in six couples during their childbearing years. There are many reasons for infertility, with equal chances it's his medical issue as it is hers. A new book, "A Baby at Last!: The Couples' Complete Guide to Getting Pregnant" (Fireside Books, Simon and Schuster), points the way for couples to get past the emotionally wrenching obstacle of infertility and finally bring home their bundle of joy.

1 Jul 2010

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

Rubicon Genomics today announced that its PicoPlex linear whole genome amplification technology was proven to be effective in an independent clinical study organized by the European Society for Human Reproduction and Embryology. At a press conference during its 26th Annual Meeting in Rome, ESHRE reported the success of its "groundbreaking proof of principle study" showing that a new approach incorporating PicoPlex could more accurately detect and characterize chromosomal abnormalities in human eggs.

1 Jul 2010

in vitro News and Research

Biodel reports preclinical test results of BIOD620 glucose-regulated or "smart" basal insulin product candidate

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Accuri Cytometers announces completion of $6 million Series E preferred stock financing

MiCK assay effective in predicting best chemotherapy response for Endometrial Cancer patients: Study

FDA grants Catheter Connections 510(k) clearance for DualCap disinfecting product

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

Musashi 2 protein predicts progression of AML and CML, identify researchers

Roche Molecular Systems receives FDA clearance for new LightCycler MRSA Advanced Test

ISCO and Sankara Nethralaya collaborate to develop "CytoCor" stem cell-derived corneal tissue

PolyMedix receives NIH grant to develop defensin-mimetic antimicrobial compounds for malaria

Research could lead to remote stimulation of cells to treat cancer or diabetes

Novel molecular pathway that regulates invasive growth, metastasis in ER-positive breast cancer discovered

Neogenix Oncology files patent application with USPTO for 16C3 antigen

Clemizole can yield high-level synergy with protease inhibitor class: Research

IRIS submits 510(k) application for clearance of iChemVELOCITY and iRICELL Urinalysis Workstation

Babies born after IVM fertility treatment more likely to be born larger than normal

Individual variants of environmental toxins can affect body's hormone systems: Research

Celsis IVT files patent infringement lawsuit against Invitrogen, CellzDirect

New guide to get pregnant

Rubicon Genomics' PicoPlex linear WGA technology proves effective in clinical study

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News